Constellation researchers will use BioTrove’s RapidFire screening and analysis system to explore a new class of drugs regulating the epigenome to alter gene expression by manipulation of chromatin’s histone proteins.
RapidFire allows for the analysis of a wide range of otherwise intractable targets such as triglycerides, lipids, fatty acids, prostaglandins, steroids, coenzyme A derivatives, neurotransmitters, anti-fungals and anti-infectives, which are difficult to study using traditional methods such as fluorescence or radiolabels, the two companies said.
Compressing the time to develop assays for this unique class of targets will enable Constellation to screen its novel epigenetic drug candidates more efficiently and effectively than current available technologies.
Mark Levin, CEO of Constellation Pharmaceuticals, said: “We believe BioTrove’s RapidFire system, which uses biologically relevant assays earlier in the discovery process, will ultimately provide us with rapid and accurate data analysis, reducing our R&D time, enhancing our ability to rapidly and accurately identify promising new lead compounds for drug development in multiple therapeutic areas.”